Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Fast Titration in the Treatment of Schizophrenia, Taiwan

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00304473
First received: March 17, 2006
Last updated: March 24, 2009
Last verified: March 2009

March 17, 2006
March 24, 2009
August 2004
Not Provided
Compare the safety and tolerability of a fast titration of quetiapine to the current titration approved by the regulatory authorities.
Same as current
Complete list of historical versions of study NCT00304473 on ClinicalTrials.gov Archive Site
Assess the efficacy of a fast titration of quetiapine to the current titration approved by the regulatory authorities.
Same as current
Not Provided
Not Provided
 
Fast Titration in the Treatment of Schizophrenia, Taiwan
Fast Titration of Quetiapine Versus Conventional Titration in the Treatment of Schizophrenia/Schizoaffective Disorder: a Randomised, Parallel Group Open Trial

Assess the efficacy of a fast titration of quetiapine to the current titration approved by the regulatory authorities.

PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Schizophrenia
Drug: Quetiapine fumarate
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
40
April 2006
Not Provided

Inclusion Criteria:

  • Signed informed consent, at least 18 years old, inpatients with relapse Schizophrenia all subtypes, and with a CGI (Clinical Global Impression) score >=4.

Exclusion Criteria:

  • Pregnancy or breast-feeding, patients treated with Clozapine within 28 days of randomization, patients with a known arrhythmia, any psychotic disorders not defined in the inclusion criteria.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Taiwan
 
NCT00304473
D1449C00001
Not Provided
Not Provided
AstraZeneca
Not Provided
Study Director: AstraZeneca Taiwan Medical Director, MD AstraZeneca
AstraZeneca
March 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP